The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.
The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.
Physicians tell Leerink most of their patients are receiving the drug. Rejections tend to be over off-label use.
The company said it plans to file its rare-disease drug with the FDA later this year, for a 2015 review.
The Supreme Court denied Teva's request to keep branded Copaxone off the market while the appeals process shakes out.